Letter

Drug prevention of hypertension

Up to a point

BMJ 2009; 338 doi: 10.1136/bmj.b2601 (Published 29 June 2009)
Cite this as: BMJ 2009;338:b2601

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Michael Schachter, senior lecturer in clinical pharmacology1
  1. 1Imperial College London, St Mary’s Hospital, London W2 1NY
  1. m.schachter{at}ic.ac.uk

    This debate parallels that on statins and cholesterol.1 Lowering low density lipoprotein (LDL) cholesterol, like lowering blood pressure, will almost always lower the risk of cardiovascular events, and the relative risk reduction will be similar regardless of starting blood pressure or LDL concentration. But the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular